Peptron, Inc. (KOSDAQ:087010)

South Korea · Delayed Price · Currency is KRW

165,500

-17,700 (-9.66%)

Sep 1, 2026, 3:30 PM KST

-46.53% (1Y)

Market Cap	3.86T -46.5%
Revenue (ttm)	6.00B +15.9%
Net Income	-20.53B
EPS	-882.92
Shares Out	23.32M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	220,852
Open	180,200
Previous Close	183,200
Day's Range	161,500 - 183,100
52-Week Range	98,000 - 392,500
Beta	0.65
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About Peptron

Peptron, Inc. engages in the development of peptide-based medicines. The company’s technologies include long acting; and SmartDepot, an ultrasonic spray drying technology for the preparation of sustained release injectable microsphere formulation of drug. It develops PAb 001 for cancer therapy; SR-Exenatide (PT320) for Parkinson’s and other neurodegenerative disease; SR-Octreotide for the treatment of acromegaly; and Dernak filler for bioequivalence. Peptron, Inc. was founded in 1997 and is headquartered in Daejeon, South Korea. [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1997

Country South Korea

Stock Exchange KOSDAQ

Ticker Symbol 087010

Full Company Profile

Financial Performance

In 2025, Peptron's revenue was 5.63 billion, an increase of 78.76% compared to the previous year's 3.15 billion. Losses were -13.82 billion, -37.26% less than in 2024.

Financial Statements